Study summary · research use only
Teriparatide: a review of its use in osteoporosis
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses recombinant teriparatide (Forteo; Forsteo) for osteoporosis in humans, describing it as an anabolic bone-forming agent. The authors report that studies have shown subcutaneous teriparatide 20 microg/day in women with postmenopausal osteoporosis, men with idiopathic or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis, and that it improves bone mineral density and alters bone formation and resorption markers, with histomorphometric effects on bone structure, strength, and quality. Over treatment periods of 11-21 months, teriparatide 20 microg/day was reported to reduce fracture risk and improve bone mineral density across these groups, with effects on vertebral fracture prevention said to persist after cessation. The authors note limitations on treatment length and high cost, suggesting teriparatide is best reserved for patients at high fracture risk or intolerant of other therapies.
Abstract
Recombinant teriparatide (Forteo; Forsteo) is an anabolic (bone forming) agent. Studies have shown that subcutaneous teriparatide 20 microg/day is effective in women with postmenopausal osteoporosis, men with idiopathic or hypogonadal osteoporosis and patients with glucocorticoid-induced osteoporosis. Teriparatide improves bone mineral density (BMD) and alters the levels of bone formation and resorption markers; histomorphometric studies showed teriparatide-induced effects on bone structure, strength and quality. Subcutaneous teriparatide 20 microg/day administered over a treatment period of 11-21 months was effective in reducing the risk of fractures in and in improving BMD in men with idiopathic or hypogonadal osteoporosis, women with postmenopausal osteoporosis and patients with glucocorticoid-induced osteoporosis. Furthermore, the beneficial effects of teriparatide on vertebral fracture prevention and BMD appear to persist following treatment cessation. Teriparatide is generally well tolerated and treatment compliance rates are favourable. However, current limitations on the length of treatment and the high acquisition cost mean that teriparatide is best reserved for the treatment of patients with osteoporosis at high risk of fracture, or for patients with osteoporosis who have unsatisfactory responses to or intolerance of other osteoporosis therapies.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.